Blood CAF22 is associated with poorer physical performance, without proving what causes it

A blood marker can be associated with physical decline without being able to predict it in an individual. A systematic review and meta-analysis of 21 studies links elevated CAF22 concentrations to slower walking and poorer physical performance scores. These findings concern aging populations or people with chronic diseases and do not demonstrate a causal link.

Person walking down a hallway for a physical performance assessment.
TrainingEditorial illustration, not study data.

A marker linked to the junction between nerve and muscle

The C-terminal agrin fragment, known as CAF22, is described in the abstract as a biomarker of neuromuscular junction degradation and sarcopenia. This junction transmits nerve signals to muscle. The biological link makes the marker interesting, but is not enough to demonstrate its usefulness in assessing an individual.

The researchers examined its associations with two objective measures: walking speed and the Short Physical Performance Battery, or SPPB, score. Their question concerned the relationship between blood concentration and performance, not the effectiveness of a treatment.

An association found across several populations

The review brings together 21 studies. The walking speed analyses include 33 cohorts and 3,136 participants. The SPPB score analyses include 28 cohorts and 2,773 participants. These figures correspond to two sets of analyses and should not be added together as though they represented distinct individuals.

The pooled correlation is −0.308 for walking speed and −0.353 for the SPPB score. In other words, higher CAF22 accompanies poorer performance on average. These coefficients represent neither a percentage loss of physical function nor an individual prediction.

The associations appear in both control groups and groups with chronic diseases. No statistically significant difference between these subgroups was detected, but this does not demonstrate their equivalence.

Not yet a test to guide individual decisions

These findings support interest in CAF22 as a candidate marker of functional decline. They do not show that an elevated concentration causes poorer performance, or that lowering this marker would improve walking.

The abstract provides neither a threshold usable in practice nor data establishing its predictive value for individuals or its added value over physical tests themselves. On its own, it therefore does not justify ordering a test to guide your training.

The authors report assessing heterogeneity, risk of bias and publication bias, but their detailed findings are not included in the excerpt provided. Funding and conflicts of interest have not been verified in this dossier.

Limitations to keep in mind

Only the PubMed abstract was consulted, not the full text. Follow-up durations, detailed population characteristics and the results of bias assessments are not available in the excerpt. The associations do not establish causality or clinical usefulness for individuals.

What we can take away

CAF22 is a candidate marker associated with poorer physical performance. This review does not demonstrate that measuring it can predict individual decline or help select an intervention.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.